THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC),...
Vous n'êtes pas connecté
THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical gemcitabine-releasing system, TAR-200 monotherapy, is well tolerated with a high...
THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC),...
A new drug-releasing system, TAR-200, eliminated tumours in 82% of patients in a phase 2 clinical trial for individuals with high-risk...
A new drug delivery system has shown remarkable success in treating a common form of bladder cancer that had stopped responding to standard therapies....
A new drug delivery system has shown remarkable success in treating a common form of bladder cancer that had stopped responding to standard therapies....
A new drug delivery system has shown remarkable success in treating a common form of bladder cancer that had stopped responding to standard therapies....
A new drug delivery system has shown remarkable success in treating a common form of bladder cancer that had stopped responding to standard therapies....
MONDAY, Aug. 18, 2025 — A new implant eliminated bladder cancer in more than 4 out of 5 high-risk cases, new clinical trial results show. The...
FRIDAY, Aug. 15, 2025 -- A considerable proportion of patients with high-grade serous cancer (HGSC) have missed opportunities for risk assessment with...
TUESDAY, Aug. 19, 2025 -- For patients 50 years or older at high cardiovascular risk without diabetes or prior stroke, an intensive systolic blood...
TUESDAY, Aug. 19, 2025 -- For patients 50 years or older at high cardiovascular risk without diabetes or prior stroke, an intensive systolic blood...